Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Deborah Collyar: What's In It for Patients?

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Mar

Today In Oncology

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Deborah Collyar: What's In It for Patients?

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Partial Gland Removal May Be an Option for Many Men With Prostate Cancer

How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World

Greater Plant Based Oil Lower Butter Intake Could Improve Risk of Cancer Related Mortality

Breast Cancer Mortality Rates May Have Stopped Declining

SGLT2 Inhibitors Could Help Protect Against Heart Failure in Patients With Cancer